News
The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...
Sarepta halted Elevidys shipments for non-ambulatory patients and paused dosing in the ENVISION trial. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able ...
Sarepta downgraded as company suspends guidance after latest Elevidys death Jun. 16, 2025 11:31 AM ET Sarepta Therapeutics, Inc. (SRPT) Stock RHHBY , RHHBF By: Dulan Lokuwithana , SA News Editor ...
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. Sarepta and ...
Sarepta Therapeutics shares dived 42% in premarket trading after the company disclosed a second reported case of acute liver failure that resulted in a death tied to its Duchenne muscular ...
Sarepta Therapeutics, Inc. stock fell after an ELEVIDYS-related death. However, click for why strong SRTP revenue growth and reset expectations lead to a Buy rating.
Sarepta Therapeutics has temporarily suspended use of the gene therapy Elevidys in non-ambulatory patients with Duchenne muscular dystrophy (DMD) after a second patient taking the drug died from ...
FDA confirms two fatal cases of liver failure in DMD patients treated with Elevidys HC Wainwright reiterates Sell rating on Sarepta, with a $10 price target Tim Melvin’s system has spotted 10X ...
Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug died. The patient was being treated for Duchenne muscular dystrophy, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback